Patients treated with microwave ablation experienced significantly fewer postoperative complications and shorter hospital stays.

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that ...

The MarketWatch News Department was not involved in the creation of this content. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

For patients with stage T1a renal cell carcinoma (T1a RCC), ablation seems to be as effective as resection or nephrectomy, according to a study published online March 3 in Radiology. Johanne ...

Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma -- Licensed SYN-020 to Rasayana Therapeutics ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

A recent study has found that severe cases COVID-19 or influenza can leave lasting changes in the lungs that increase the ...

Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American Society of Clinical ...